GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Embla Medical hf (OTCPK:OSSFF) » Definitions » Cash Flow from Financing

OSSFF (Embla Medical hf) Cash Flow from Financing : $40.8 Mil (TTM As of Jun. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Embla Medical hf Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Jun. 2024, Embla Medical hf paid $0.0 Mil more to buy back shares than it received from issuing new shares. It spent $9.2 Mil paying down its debt. It paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.0 Mil from paying cash dividends to shareholders. It received $0.0 Mil on other financial activities. In all, Embla Medical hf spent $9.2 Mil on financial activities for the three months ended in Jun. 2024.


Embla Medical hf Cash Flow from Financing Historical Data

The historical data trend for Embla Medical hf's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Embla Medical hf Cash Flow from Financing Chart

Embla Medical hf Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -29.30 51.86 -51.07 3.79 -40.96

Embla Medical hf Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.51 -17.09 -15.26 88.27 -15.14

Embla Medical hf Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Embla Medical hf's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Embla Medical hf's Cash from Financing for the quarter that ended in Jun. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $40.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Embla Medical hf  (OTCPK:OSSFF) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Embla Medical hf's issuance of stock for the three months ended in Jun. 2024 was $0.0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Embla Medical hf's repurchase of stock for the three months ended in Jun. 2024 was $0.0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Embla Medical hf's net issuance of debt for the three months ended in Jun. 2024 was $-9.2 Mil. Embla Medical hf spent $9.2 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Embla Medical hf's net issuance of preferred for the three months ended in Jun. 2024 was $0.0 Mil. Embla Medical hf paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Embla Medical hf's cash flow for dividends for the three months ended in Jun. 2024 was $0.0 Mil. Embla Medical hf received $0.0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Embla Medical hf's other financing for the three months ended in Jun. 2024 was $0.0 Mil. Embla Medical hf received $0.0 Mil on other financial activities.


Embla Medical hf Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Embla Medical hf's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Embla Medical hf Business Description

Traded in Other Exchanges
Address
Grjothals 5, Reykjavik, ISL
Ossur hf is engaged in the design, development, manufacture, and sale of prosthetics and bracing & support products. The company's products improve mobility through technologies in the field of braces, supports, prosthetic limbs, and compression therapy. Its segments are the Bracing & Supports and Prosthetics segment. The bracing & support products are used to support joints and other body parts for therapeutic and preventative purposes. The Prosthetics segment includes artificial limbs and related products for individuals born without limbs. Its geographical segments are the Americas; Europe, the Middle East & Africa (EMEA); and the Americas & Asia-Pacific (APAC), of which the Americas generate nearly half of the company's revenue.